CHMP 建议批准 SPEVIGO® 用于成人/青少年全身性脓疱型银屑病发作预防。 CHMP recommends SPEVIGO® approval for generalized pustular psoriasis flare prevention in adults/adolescents.

欧洲药品管理局人用药品委员会 (CHMP) 建议批准 SPEVIGO®（spesolimab）注射剂的新适应症，用于预防 12 岁及以上成人和青少年的全身性脓疱型银屑病 (GPP) 发作。 The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a new indication for SPEVIGO® (spesolimab) injection, targeting generalized pustular psoriasis (GPP) flares prevention in adults and adolescents aged 12 and above. SPEVIGO® 是首个针对 GPP 的靶向疗法，在 EFFISAYIL® 2 试验中，与安慰剂相比，它将 GPP 发作风险降低了 84%。 SPEVIGO®, the first targeted therapy for GPP, reduced GPP flare risk by 84% compared to placebo in the EFFISAYIL® 2 trial.